Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Divestments (2020 - 2021)

Historic Divestments for Myriad Genetics (MYGN) over the last 2 years, with Q3 2021 value amounting to $379.1 million.

  • Myriad Genetics' Divestments rose 167981.22% to $379.1 million in Q3 2021 from the same period last year, while for Dec 2024 it was $379.1 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $8.8 million for FY2024, which is N/A changed from last year.
  • Myriad Genetics' Divestments amounted to $379.1 million in Q3 2021, which was up 167981.22% from $21.3 million recorded in Q3 2020.
  • Over the past 5 years, Myriad Genetics' Divestments peaked at $379.1 million during Q3 2021, and registered a low of -$21.3 million during Q2 2020.